Clinical Report: FDA expands treatment in nephrotic syndrome
Overview
The FDA has approved obinutuzumab (Gazyva) for reducing relapse risk in patients aged 2 and older with frequently relapsing or steroid-dependent idiopathic nephrotic syndrome. This approval is based on the INSHORE trial, which demonstrated that 73% of patients receiving obinutuzumab met the primary efficacy endpoint compared to standard treatment.
Background
Idiopathic nephrotic syndrome is a significant pediatric kidney disorder characterized by proteinuria, leading to complications such as low albumin levels, high cholesterol, and increased risk of infections and blood clots. The condition predominantly affects children aged 2 to 7 years and has an estimated annual incidence of 1 to 4 cases per 100,000 pediatric patients.
Data Highlights
Study
Population
Primary Endpoint
Obinutuzumab Efficacy
INSHORE
85 patients aged 2+
Urine protein-creatinine ratio ≤0.2 g/g at Week 52
73% met endpoint
Key Findings
Obinutuzumab is approved for patients aged 2 years and older with frequently relapsing or steroid-dependent idiopathic nephrotic syndrome.
The INSHORE trial showed a statistically significant greater proportion of patients on obinutuzumab reached the primary efficacy endpoint compared to standard treatment.
Common side effects of obinutuzumab include infections, infusion-related reactions, and neutropenia.
The drug carries boxed warnings for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.
Obinutuzumab has previously received Breakthrough Therapy, Orphan Drug, and Priority Review designations.
Clinical Implications
Clinicians should be aware of the potential side effects and the need for monitoring during treatment with obinutuzumab.
Conclusion
The FDA's approval of obinutuzumab provides a new treatment option for managing frequently relapsing or steroid-dependent idiopathic nephrotic syndrome.
U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.
